Scandinavian journal of immunology

How COVID-19 mRNA Vaccines May Make Tumors More Responsive to Immune Therapy Blocking PD-1/PD-L1

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

SARS-CoV-2 mRNA vaccines may reprogram the tumor microenvironment.

  • These vaccines are associated with enhanced efficacy of PD-1/PD-L1 blockade.
  • The findings suggest potential applications for mRNA technology in cancer treatment.
  • Reprogramming of the tumor microenvironment could lead to improved immune responses.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '25
COVID-19 mRNA vaccines may help tumors respond better to immune checkpoint therapy
🏆 top 0.1% journal
cited by 49 papers
journal article
Nov '21
PD-1 blockade may reduce immune problems after COVID-19 and boost the immune response against the virus
top 5% journal
cited by 75 papers
research support, non-u.s. gov't
Jan '22
Immune responses six months after COVID-19 vaccination in cancer patients receiving immune checkpoint therapy with or without chemotherapy
top 2% journal
cited by 16 papers
research support, non-u.s. gov't
Nov '25
Blocking PD-1/PD-L1 and IL-33/ST2 pathways as a promising breast cancer immunotherapy
top 20% journal
cited by 4 papers
journal article
Dec '25
A peptide from the COVID-19 spike protein boosts immune responses and improves anti-PD-L1 cancer therapy against melanoma
top 10% journal
journal article
Sep '24
Types and Locations of Cells That Respond to PD-1/PD-L1 Blockade
top 2% journal
cited by 8 papers
research support, non-u.s. gov't
Oct '25
PD-L1 targeting bispecific T cell engager kills PD-L1 tumor cells while blocking PD-1 and changing the tumor immune environment
top 2% journal
cited by 1 paper
journal article
Nov '25
Improving PD-1/PD-L1 cancer therapy by targeting sugar-binding proteins to boost immune response
top 5% journal
journal article
Nov '21
Detailed Mapping of Antibody Targets on the COVID-19 Vaccine Spike Protein
top 20% journal
cited by 26 papers
research support, non-u.s. gov't
Mar '21
Immunotherapy and its early signs in the immune system
top 20% journal
cited by 3 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the mrna technology brief

issue #43
A common antibiotic switches self-amplifying RNA vaccines on and off — with 10x range between states
2 days ago7 studies
issue #42
A single LNP dose achieved 49% liver gene editing in mice — without viral vectors
1 week ago7 studies
issue #41
Buffer choice affects mRNA vaccine performance by 40% after freeze-thaw cycles
2 weeks ago7 studies
issue #40
mRNA vaccine boosted cancer immunotherapy survival rates by 70-80% in mice
3 weeks ago7 studies
issue #39
Combo flu-COVID mRNA vaccine shows durable immunity through 6 months in adults 50+
4 weeks ago7 studies
issue #38
Heart gene editing reaches 36% of muscle cells with targeted injection approach
5 weeks ago7 studies
issue #36
Fractalkine-targeted mRNA nanoparticles hit 95% of killer T cells in mice
7 weeks ago7 studies
issue #35
AI designed lipid nanoparticles achieve 13.5x better cartilage targeting than clinical benchmark
8 weeks ago7 studies
issue #34
Scientists create PEG-free RNA nanoparticles that cut inflammation by 90%
9 weeks ago7 studies
issue #33
Salt-loaded nanoparticles boost mRNA delivery by popping endosomes like water balloons
10 weeks ago7 studies
explore the archive
See more issues from the mrna technology brief